Abstract: The present invention includes the use of an antagonist of vascular endothelial growth factor receptor (VEGFR) in combination with an antagonist of vascular endothelial cadherin (VE-cadherin) to modulate angiogenesis. Included is the use of the VEGFR antagonist and the antagonist of VE-cadherin in a manner so as to prevent or ameliorate toxicity associated with the use of VE-cadherin antagonist. The present invention also comprises the use of a VEGFR antagonist and a VE-cadherin antagonist for treating, with reduced toxicity, diseases associated with angiogenesis, which include but are not limited to neoplastic diseases, autoimmune diseases and collagen vascular diseases, as well as the use of a VEGFR antagonist for the treatment of disease states associated with pathological vascular permeability which include, but are not limited to, ARDS, edema states and related conditions.